Patents by Inventor Damir Vidovic

Damir Vidovic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS EMPLOYING ALTERNATIVE READING FRAME POLYPEPTIDES FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASE
    Publication number: 20150344543
    Abstract: Provided are alternative reading frame (ARF) polypeptides as well as antigen presenting cell (APC) and dendritic cell (DC) based compositions that comprise ARF polypeptides. ARF polypeptides and ARF polypeptide-based compositions are useful in the treatment of cancer and infectious disease.
    Type: Application
    Filed: May 29, 2015
    Publication date: December 3, 2015
    Inventors: THOMAS GRADDIS, REINER LAUS, MICHAEL DIEGEL, DAMIR VIDOVIC
  • Compositions employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
    Patent number: 9051385
    Abstract: Provided are alternative reading frame (ARF) polypeptides as well as antigen presenting cell (APC) and dendritic cell (DC) based compositions that comprise ARF polypeptides. ARF polypeptides and ARF polypeptide-based compositions are useful in the treatment of cancer and infectious disease.
    Type: Grant
    Filed: October 5, 2009
    Date of Patent: June 9, 2015
    Assignee: DENDREON CORPORATION
    Inventors: Thomas Graddis, Reiner Laus, Michael Diegel, Damir Vidovic
  • HLA-DR specific antibodies, compositions and methods
    Patent number: 8354507
    Abstract: HLA-DR-specific monoclonal antibodies are provided that are capable of inducing apoptosis in HLA-DR-expressing tumor cells. Certain exemplary HLA-DR-specific antibodies exhibit reduced levels of immunosuppressive activity. Antibodies of the present invention will find use in diagnostic methods as well as in compositions and methods for the treatment of cancers associated with HLA-DR expressing tumor cells.
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: January 15, 2013
    Assignee: Dendreon Corporation
    Inventors: Cathy McMahan, Lara Porter Stepan, Reiner Laus, Damir Vidovic
  • Compositions Employing Alternative Reading Frame Polypeptides for the Treatment of Cancer and Infectious Disease
    Publication number: 20100034842
    Abstract: Provided are alternative reading frame (ARF) polypeptides as well as antigen presenting cell (APC) and dendritic cell (DC) based compositions that comprise ARF polypeptides. ARF polypeptides and ARF polypeptide-based compositions are useful in the treatment of cancer and infectious disease.
    Type: Application
    Filed: October 5, 2009
    Publication date: February 11, 2010
    Inventors: Thomas Graddis, Reiner Laus, Michael Diegel, Damir Vidovic
  • Compositions and methods for dendritic cell-based immunotherapy
    Patent number: 7659117
    Abstract: Disclosed are immunostimulatory fusion proteins and methods for generating protective DC-induced, T cell-mediated immune responses in vitro and in vivo. The immunostimulatory fusion proteins comprise a polypeptide antigen component and an immunostimulatory component derived from the intracellular domain of the HER-2 protein. Also disclosed are immunostimulatory compositions comprising dendritic cells pulsed with such an immunostimulatory fusion protein and methods for immunotherapy using the compositions.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: February 9, 2010
    Assignee: Dendreon Corporation
    Inventors: Reiner Laus, Damir Vidovic, Thomas Graddis
  • Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
    Patent number: 7597894
    Abstract: Provided are alternative reading frame (ARF) polypeptides as well as antigen presenting cell (APC) and dendritic cell (DC) based compositions and methods that employ alternative reading frame polypeptides. ARF polypeptides and ARF polypeptide-based compositions and methods are useful in the treatment of cancer and infectious disease.
    Type: Grant
    Filed: March 5, 2004
    Date of Patent: October 6, 2009
    Assignee: Dendreon Corporation
    Inventors: Thomas Graddis, Reiner Laus, Michael Diegel, Damir Vidovic
  • Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation
    Publication number: 20060292165
    Abstract: Compositions and methods for eliciting an in vivo cytotoxic lymphocyte (CTL) response against a modified soluble protein antigen are disclosed. The modified soluble protein antigen comprises an added peptidic sequence which facilitates entry of the modified antigen into antigen presenting cells (APC).
    Type: Application
    Filed: June 16, 2006
    Publication date: December 28, 2006
    Inventors: Reiner Laus, Itzhak Hakim, Damir Vidovic
  • Compositions and methods for dendritic cell-based immunotherapy
    Patent number: 7060279
    Abstract: Disclosed are immunostimulatory fusion proteins and methods for generating protective DC-induced, T cell-mediated immune responses in vitro and in vivo. The immunostimulatory fusion proteins comprise a polypeptide antigen component and an immunostimulatory component derived from the intracellular domain of the HER-2 protein. Also disclosed are immunostimulatory compositions comprising dendritic cells pulsed with such an immunostimulatory fusion protein and methods for immunotherapy using the compositions.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: June 13, 2006
    Assignee: Dendreon Corporation
    Inventors: Reiner Laus, Damir Vidovic, Thomas Graddis
  • Compositions and methods for dendritic cell-based immunotherapy
    Publication number: 20050232932
    Abstract: Disclosed are immunostimulatory fusion proteins and methods for generating protective DC-induced, T cell-mediated immune responses in vitro and in vivo. The immunostimulatory fusion proteins comprise a polypeptide antigen component and an immunostimulatory component derived from the intracellular domain of the HER-2 protein. Also disclosed are immunostimulatory compositions comprising dendritic cells pulsed with such an immunostimulatory fusion protein and methods for immunotherapy using the compositions.
    Type: Application
    Filed: June 3, 2005
    Publication date: October 20, 2005
    Inventors: Reiner Laus, Damir Vidovic, Thomas Graddis
  • HLA-DR specific antibodies, compositions and methods
    Publication number: 20050208048
    Abstract: HLA-DR-specific monoclonal antibodies are provided that are capable of inducing apoptosis in HLA-DR-expressing tumor cells. Certain exemplary HLA-DR-specific antibodies exhibit reduced levels of immunosuppressive activity. Antibodies of the present invention will find use in diagnostic methods as well as in compositions and methods for the treatment of cancers associated with HLA-DR expressing tumor cells.
    Type: Application
    Filed: December 15, 2004
    Publication date: September 22, 2005
    Applicant: DENDREON CORPORATION
    Inventors: Cathy McMahan, Lara Stepan, Reiner Laus, Damir Vidovic
  • Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
    Publication number: 20050112134
    Abstract: Provided are alternative reading frame (ARF) polypeptides as well as antigen presenting cell (APC) and dendritic cell (DC) based compositions and methods that employ alternative reading frame polypeptides. ARF polypeptides and ARF polypeptide-based compositions and methods are useful in the treatment of cancer and infectious disease.
    Type: Application
    Filed: March 5, 2004
    Publication date: May 26, 2005
    Applicant: DENDREON CORPORATION
    Inventors: Thomas Graddis, Reiner Laus, Michael Diegel, Damir Vidovic
  • Selective apoptosis of neoplastic cells by an HLA-DR specific monoclonal antibody
    Patent number: 6416958
    Abstract: Anti-human major histocompatibility complex (MHC) class II, HLA-DR-specific monoclonal antibodies which can induce apoptosis of HLA-DR positive cells are disclosed. The antibodies are used to specifically eliminate HLA-DR antigen positive tumor cells by cross-linking of HLA-DR. Also disclosed are methods for treating cancer using such antibodies, and compositions containing them.
    Type: Grant
    Filed: August 13, 2001
    Date of Patent: July 9, 2002
    Assignee: Dendreon Corporation
    Inventors: Damir Vidovic, Reiner Laus
  • Compositions and methods for dendritic cell-based immunotherapy
    Publication number: 20020061310
    Abstract: Disclosed are immunostimulatory fusion proteins and methods for generating protective DC-induced, T cell-mediated immune responses in vitro and in vivo. The immunostimulatory fusion proteins comprise a polypeptide antigen component and an immunostimulatory component derived from the intracellular domain of the HER-2 protein. Also disclosed are immunostimulatory compositions comprising dendritic cells pulsed with such an immunostimulatory fusion protein and methods for immunotherapy using the compositions.
    Type: Application
    Filed: March 30, 2001
    Publication date: May 23, 2002
    Inventors: Reiner Laus, Damir Vidovic, Thomas Graddis
  • Selective apoptosis of neoplastic cells by an HLA-DR specific monoconal antibody
    Publication number: 20010053360
    Abstract: Anti-human major histocompatibility complex (MHC) class II, HLA-DR-specific monoclonal antibodies which can induce apoptosis of HLA-DR positive cells are disclosed. The antibodies are used to specifically eliminate HLA-DR antigen positive tumor cells by cross-linking of HLA-DR. Also disclosed are methods for treating cancer using such antibodies, and compositions containing them.
    Type: Application
    Filed: August 13, 2001
    Publication date: December 20, 2001
    Applicant: Genelabs Technologies, Inc.
    Inventors: Damir Vidovic, Reiner Laus